Bedel Financial Consulting’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.1M Hold
18,400
2.07% 6
2026
Q1
$16.9M Buy
18,400
+1,000
+6% +$1.01M 1.91% 7
2025
Q4
$71.8K Hold
17,400
0.01% 286
2025
Q3
$578K Hold
17,400
0.07% 143
2025
Q2
$814K Hold
17,400
0.11% 106
2025
Q1
$980K Hold
17,400
0.14% 91
2024
Q4
$681K Buy
17,400
+2,200
+14% +$1.82M 0.09% 121
2024
Q3
$22.1K Hold
15,200
﹤0.01% 258
2024
Q2
$19.5K Hold
15,200
﹤0.01% 251
2024
Q1
$93.6K Hold
15,200
0.01% 248
2023
Q4
$521K Buy
+15,200
New +$8.87M 0.1% 124

Other funds holding LLY

Bedel Financial Consulting's LLY Position: Q2 2026 in Review

Bedel Financial Consulting increased its Eli Lilly (LLY) stake by 0.19% in Q2 2026, buying an estimated $636K and bringing the position to 328,198 shares worth $394M. The position accounts for 36.97% of the portfolio, ranked #1.

Bedel Financial Consulting first reported a position in LLY in Q4 2017 and has held it in 35 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Bedel Financial Consulting held 328,198 shares of Eli Lilly worth $394M as of Q2 2026.
  • Bedel Financial Consulting bought 622 Eli Lilly shares in Q2 2026, an estimated $636K.
  • Eli Lilly made up 36.97% of Bedel Financial Consulting's portfolio in Q2 2026, its #1 holding.
  • Bedel Financial Consulting first reported a position in Eli Lilly in Q4 2017 and has held it in 35 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Bedel Financial Consulting's 13F filing for Q2 2026, filed 29 Jul 2026.